CalRx® Naloxone delivers significant cost savings to California
Since its launch in May 2024, CalRx®-branded naloxone has become the primary product supplied for California’s Naloxone Distribution Project (NDP), which provides lifesaving medication to harm reduction groups, schools, emergency responders, and more – at no cost to qualifying organizations.
By securing 4 mg CalRx naloxone nasal spray from the manufacturer, Amneal Pharmaceuticals, at just $24 per twin-pack, the CalRx® Naloxone Access Initiative has saved California several million dollars to date, as highlighted by the monthly CalRx® Naloxone State Savings Tracker:
About this data:
- CalRx-branded naloxone nasal spray became available in California in May 2024.
- Monthly sales data for CalRx/Amneal naloxone is provided by Amneal Pharmaceuticals, while data on NDP purchases include units from the non-CalRx®-branded supplier and CalRx®-branded/Amneal® branded units.
- State savings are calculated by comparing the $24 cost per unit of CalRx® 4 mg naloxone nasal spray to the $41 cost per unit of the historical supplier.
- Cumulative savings reflect the total sum of monthly state savings since the launch of CalRx® Naloxone Access Initiative.
- Indirect savings to the NDP from the launch of CalRx ® Naloxone (i.e., estimated savings resulting from downward price pressure of other vendors in the market) to the end of the 2024-2025 fiscal year is $39.3 million.